Results 251 to 260 of about 401,950 (315)

Actionable driver gene alterations in early-stage non-small cell lung cancer: a review. [PDF]

Ther Adv Med Oncol
Attili I, Pisapia P, Spitaleri G, Aliaga PT, Del Signore E, Napoli VM, Passaro A, Malapelle U, Troncone G, de Marinis F.   +9 more
europepmc   +1 more source

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky, Stefan Engeli, Stefanie M. Bode‐Böger, Felix Koop, Martin Schulze Westhoff, Sebastian Schröder, Carsten Schumacher, Thorben Pape, Dirk O. Stichtenoth, Johannes Heck   +9 more
wiley   +1 more source

Renal Function, Atrial Cardiopathy, and Their Joint Association with Mortality in the General Population. [PDF]

J Clin Med
Zaho T, Soliman MZ, Mostafa MA, Shatta AE, Attia MA, Elbadawy MS, Kazibwe R, Soliman EZ.   +7 more
europepmc   +1 more source

EGFR downregulation

Reactome - a curated knowledgebase of biological pathways, 2008
openaire   +1 more source

A real‐world data‐driven approach to optimizing enoxaparin dosing in burn patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation‐based (EQ) dosing and propose an optimized dosing ...
Babajide Shenkoya, Venkata Yellepeddi, Ann Marie B. Prazak, Mathangi Gopalakrishnan   +3 more
wiley   +1 more source

Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling. [PDF]

Transl Cancer Res
Bai Y, Gong Y, Cui R, Deng Q, Zhao X, Liu C, Dong L.   +6 more
europepmc   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

Role of genetic alterations on outcomes for pulmonary resection in oligometastatic non-small cell lung cancer. [PDF]

J Thorac Dis
Hooda Z, Werner R, Ries S, Eisenberg M, Hofstetter W, Mehran R, Rajaram R, Rice D, Swisher S, Vaporciyan A, Walsh G, Opitz I, Mitchell KG, Antonoff MB.   +13 more
europepmc   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Treatment options for EGFR mutation-positive NSCLC patients with leptomeningeal metastases after third-generation TKI resistance: a retrospective real-world study. [PDF]

Ther Adv Med Oncol
Yun W, Liu A, Wen J, Zhao K, Meng X.
europepmc   +1 more source